Impact of FOLFOXIRI and bevacizumab (bev) compared to FOLFOX and bev on health related quality of life (HRQOL) in patients with metastatic colorectal cancer (MCRC): Analysis of the CHARTA-AIO 0209 trial.
Julia Quidde(Universität Hamburg), Alexander Stein(Universität Hamburg), Benjamin Garlipp(University Hospital Magdeburg), Jörg Steighardt, Thomas Goehler(Onkozentrum Dresden), Heinz‐Gert Hoeffkes(Klinikum Fulda), Thomas Edelmann(Praxis für Hämatologie und Onkologie), Ulrich Kaiser(University of Applied Sciences Landshut), Carsten Bokemeyer(Universität Hamburg), Arndt Vogel(Princess Margaret Cancer Centre), Helmut Forstbauer, Stephan Kanzler(Leopoldina Krankenhaus Schweinfurt), Carla Hannig(Praxis für Hämatologie und Onkologie), Christian Junghanß(University of Rostock), Jörn Rüssel(Martin Luther University Halle-Wittenberg), Hans‐Joachim Schmoll(Martin Luther University Halle-Wittenberg), Michael Schaefers(Praxis für Hämatologie und Onkologie), Malte Leithaeuser(University of Rostock), Axel Florschütz(Städtisches Klinikum Dessau), Bert Hildebrandt(Charité - Universitätsmedizin Berlin)
Cited by 2
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Autopsy Findings and Venous Thromboembolism in Patients With COVID-19
|Annals of Internal Medicine|2020|2.4k
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2022|1.4k